e0b0b87d-1125-4834-8133-5d719f1fd255
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.500
- G2M_CHECKPOINT+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- MITOTIC_SPINDLE+0.400
- ALLOGRAFT_REJECTION+0.300
- E2F_TARGETS+0.300
- MTORC1_SIGNALING+0.300
- PEROXISOME+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
Top 10 suppressed
- ANGIOGENESIS-0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- COAGULATION-0.400
- MYOGENESIS-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- APICAL_JUNCTION-0.300
- HYPOXIA-0.300
- P53_PATHWAY-0.300
- CHOLESTEROL_HOMEOSTASIS-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d01f4531-b145-414b-bc1c-0f1a148b771e | — | — | 0.850 |
| 2 | 6b375859-116e-4a5e-b5b4-994a56cc9a75 | — | — | 0.834 |
| 3 | 223494f1-6c0b-446e-998d-53b3b4d0da1a | — | — | 0.833 |
| 4 | SRR12202424 | — | — | 0.821 |
| 5 | GSM6454730 | — | D | 0.819 |
| 6 | b652254e-228b-40d4-be79-536ad87dad69 | — | — | 0.805 |
| 7 | SRR9879266 | — | cohortMD2 | 0.798 |
| 8 | TCGA-A8-A081-01A-11R-A00Z-07 | — | C | 0.792 |
| 9 | s0095121 | — | — | 0.790 |
| 10 | 87dc0bab-b318-47ec-a9a3-819a7388e731 | — | — | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |